Tara Sanft Discusses Advancements in HER2+ Treatments

October 4, 2016

Video

Tara Sanft, MD, of Smilow Cancer Hospital at Yale-New Haven Hospital describes some of the new treatments for patients with HER2+ breast cancer.

Among the drugs available, Sanft explains that pertuzumab used along with trastuzumab and chemotherapy, produces a better chance that the patient will have a pathologic complete response (pCR). Patients who reach pCR go on to have a better prognosis.

Related Content

Neoadjuvant Niraparib/Dostarlimab Combo May Yield pCRs in BRCS+, ER+/HER2- Breast Cancer

Ariana Pelosci

December 19th 2024

Article

Additional exploration may help fully realize the impact of combining immunologic approaches with PARP inhibition, says one expert.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer

October 2nd 2023

Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Addition of Perioperative Atezolizumab Does Not Improve EFS in TNBC

Jason Broderick

December 16th 2024

Article

Perioperative atezolizumab did not improve outcomes in patients with triple-negative breast cancer.

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer

January 16th 2023

Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Immediate Surgery Lowers Local Recurrence in Older Breast Cancer Population

Russ Conroy

December 14th 2024

Article

“This benefit in local recurrence translates into a later difference in distant recurrence and breast cancer [mortality], but it’s only apparent with long follow-up,” according to the study author.